Tirzepatide 15mg
Dual GIP/GLP-1 receptor agonist — mid-range vial covering full titration through early maintenance.
Titration: wks 1–4 @ 2.5 mg, wks 5–8 @ 5 mg, wks 9–10 @ 7.5 mg
Key Benefits
activates two complementary incretin pathways for superior metabolic response vs GLP-1 monotherapy
SURMOUNT-1 demonstrated 22.5% mean body weight reduction at 72 weeks, the highest of any approved weight-loss drug
reduces HbA1c by up to 2.46% in T2D research models, outperforming semaglutide in head-to-head trials
dual receptor activation produces stronger satiety signaling than single-receptor GLP-1 agonists
Recommended Injection Sites
Optimal injection locations for Tirzepatide 15mg based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
FDA-approved clinical injection site for tirzepatide. Largest SubQ depot; most consistent absorption for weekly dosing.
Second preferred site per clinical guidelines. Slightly slower Cmax but equivalent AUC over weekly dosing interval.
Third approved site per Mounjaro/Zepbound prescribing information. Requires assistance for consistent placement.
Rotate weekly injection site systematically — abdomen → thigh → upper arm. Never inject the same exact spot twice in a row.
- IV administration
- Intramuscular injection (alters pharmacokinetics)
- Navel or waistband area
- Injection into skin folds with active lipodystrophy
Active Signaling Pathway
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 15mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. It acts as a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation adds complementary metabolic effects — enhanced insulin secretion, reduced glucagon, and direct adipocyte signaling — producing greater weight reduction than GLP-1 agonism alone.
Clinical Context
Tirzepatide represents the second generation of incretin-based therapy. Its dual mechanism — acting on both GIP and GLP-1 receptors — produces metabolic effects that exceed GLP-1 monotherapy in head-to-head trials. The 15mg vial bridges the full titration phase and the initial maintenance step, reducing the number of vials needed in the first 12 weeks of a protocol.
Research Highlights
- SURMOUNT-1 trial: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — the highest of any approved weight-loss drug at time of publication
- SURPASS-2 trial: tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg
- FDA approved as Mounjaro (T2D) in 2022 and Zepbound (obesity) in 2023
- Dual receptor mechanism produces additive metabolic effects beyond GLP-1 monotherapy
Storage & Reconstitution
Titration: 2.5 mg/week for 4 weeks, then 5 mg/week for 4 weeks, then 7.5 mg/week. This 15mg vial covers approximately 10–12 weeks of titration and early maintenance.